Last verified: 2026-03-27. Reviewed by Angelica Bottaro.
Known For: Founded by Dr. Zahida Tayyib (20+ years in psychiatry, El Camino Health affiliated) as an integrative practice that pairs TMS with yoga, Tai-Chi, and group therapy; cross-cultural patient focus tailored to Silicon Valley’s diverse population, with a particular emphasis on women’s mental health.
| Location | Mountain View, California |
| Address | 525 South Drive, Suite 207 Mountain View, CA 94041 |
| Phone | 650-969-6772 |
| Website | mvptms.com |
| Treatments | TMS therapy (transcranial magnetic stimulation) — BrainsWay Deep TMS |
| Protocols | Deep TMS |
| Conditions Treated | Treatment-resistant depression (TRD) · OCD · Anxious depression · Adolescent MDD (ages 15–21) · Smoking cessation |
| Insurance | Most major commercial plans, Medicare Part B, and Tricare typically cover TMS for treatment-resistant depression after prior authorization — verify with this clinic. |
| Cost | $300–500/session cash; $0–250/session typical insurance copay |
| Course | 36 sessions over 6–9 weeks (standard rTMS) |
HealingMaps Take: BrainsWay Deep TMS opens up OCD treatment on-label — a meaningful advantage over standard NeuroStar-only clinics, since only the H7 coil holds the FDA OCD clearance. Patients pursuing TMS for OCD or anxious depression should confirm the H7 coil specifically (vs the H1 coil used for MDD).
Market Position: One of the TMS providers in the Mountain View, CA metro offering Deep TMS — relevant for OCD seekers (only Deep TMS H7 holds the standalone FDA OCD clearance) and patients who want non-focal deeper coil penetration.
The TMS device a clinic operates determines which conditions can be treated on-label. The protocols offered here:
| Protocol | Session length | FDA-cleared for |
|---|---|---|
| Standard rTMS (10 Hz) | 19–37 min | TRD, anxious depression, adolescent MDD (15–21) |
| Deep TMS (H-coil) | ~20 min | TRD, OCD (H7), anxious depression, smoking cessation (H4) |
For a full breakdown of TMS devices (NeuroStar, BrainsWay, MagVenture, Magstim, Nexstim) and how protocols differ, see our complete guide to TMS therapy.
Cash-pay TMS sessions in Mountain View, CA typically run $300 to $500 per session, with the full 36-session course costing $7,200 to $15,000. Premium-metro clinics (NYC, San Francisco, Los Angeles, Boston) charge 30 to 50 percent more. With insurance, copays typically run $0 to $250 per session depending on your deductible status; most patients with employer-sponsored PPO plans pay $500 to $3,000 out-of-pocket for a full course. Many independent clinics offer 10 to 25 percent package discounts for cash-pay patients. TMS is HSA- and FSA-eligible. Contact this clinic directly for their specific cash-pay rates and in-network status with your insurer.
Most major commercial insurance plans (BCBS, Aetna, Cigna, UnitedHealthcare, Anthem, Humana), Medicare Part B, and Tricare cover TMS for treatment-resistant major depressive disorder. UnitedHealthcare typically requires 3 failed antidepressant trials; most other carriers require 2. Pre-authorization is mandatory across all major carriers. Coverage for off-label conditions (PTSD, fibromyalgia, bipolar depression, migraine) is rarely approved. Contact this clinic to verify in-network status with your specific insurer and to learn about their prior-authorization handling.
The “TMS dip” is a patient-coined term for temporary worsening of mood or symptom intensification that some patients experience roughly mid-course (commonly between sessions 10 and 20) before clinical improvement begins. It’s not a sign that TMS is failing — it usually resolves with continued treatment. If you experience the dip, tell your clinician immediately. They may adjust intensity, frequency, or coil position. Importantly, dropping out before session 20 substantially reduces overall response rate. Patients who push through the mid-course dip generally have better outcomes than those who quit early.
Yes. TMS requires no anesthesia, no sedation, and no IV access. Patients drive themselves to sessions, return to work, school, or normal activities immediately afterward, and need no chaperone or recovery period. This is the single largest patient-experience advantage TMS holds over ketamine therapy and ECT. Many patients schedule sessions on lunch breaks. The only post-session sensation is mild scalp tenderness for the first few sessions, which decreases substantially as scalp nerves desensitize.
This clinic operates BrainsWay Deep TMS. The device determines what conditions can be treated on-label. For OCD, only BrainsWay Deep TMS H7 has a standalone FDA clearance. For adolescents 15–21, only NeuroStar (since March 2024) and BrainsWay (since November 2025) hold the relevant indications. Ask the clinic which device they operate before booking.
Possibly — but only BrainsWay Deep TMS using the H7 coil holds a standalone FDA clearance for OCD (granted via the De Novo pathway in 2018). MagVenture’s Cool D-B80 has an OCD adjunct clearance. Standard NeuroStar (figure-8 coil) is not FDA-cleared for OCD. This clinic appears to use BrainsWay Deep TMS, which is the FDA-cleared device for OCD. The full OCD course is 29 sessions over 6 weeks with symptom-provocation protocols.
The FDA has cleared TMS for adolescents 15 to 21 with major depressive disorder. NeuroStar received the first adolescent clearance in March 2024; BrainsWay Deep TMS followed in November 2025. There is no current FDA clearance for ages 12 through 14. Real-world evidence from NeuroStar’s clearance documentation cited 78 percent of treated adolescents achieving clinically meaningful improvement. Contact this clinic to confirm whether their device holds the adolescent indication and whether they treat patients in this age range.

People with treatment-resistant health disorders can finally find relief from their symptoms through the use of transcranial magnetic stimulation (TMS) therapy at Mountain View Psychiatry and TMS. The TMS and psychiatric center utilizes the breakthrough therapy for conditions that cannot be treated using traditional medicine, such as depression, bipolar disorder, and more.
⚠ FDA-cleared indications for TMS therapy: treatment-resistant major depressive disorder (MDD), obsessive-compulsive disorder (OCD, Deep TMS only), anxious depression, short-term smoking cessation, and adolescent MDD (ages 15–21). Use of TMS for other conditions including PTSD, bipolar depression, fibromyalgia, and other indications is off-label — not currently FDA-cleared for those specific indications. Discuss your condition with the clinic to understand insurance coverage and clinical evidence.
Interested in joining a Psychedelics Clinical Trial? Sign up here now and we will connect you with a clinical trial in your area when one becomes available.
Mountain View Psychiatry and TMS is led by Dr. Zahida Tayyib. Dr. Tayyib and the team at the center take pride in offering the latest in medical technologies to battle disorders that are notoriously difficult to treat. Their main goal is to help as many people as possible finally find healing from their afflictions.
Want to Become a Certified Psychedelic Therapist or Coach? Click Here to Learn How
Learn more about this treatment:
Leave a Reply